William R. Faber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William R. Faber has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Henry J.C. de Vries
2 shared publicationsJim E. Zeegelaar
2 shared publicationsA. J. Jensema
Departments of Dermatology
1 shared publicationA.H.J. Kolk
KIT Biomedical Research, Royal Tropical Institute, Amsterdam, The Netherlands
1 shared publication- Aldert Bart
Academisch Medisch Centrum, Amsterdam, The Netherlands
1 shared publication Annigje J. Jensema
1 shared publication
Latest Publications
- Open Access
- 1 March 2015
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 21 (3) , 497-499
Buruli Ulcer in Traveler from Suriname, South America, to the Netherlands
We report Buruli ulcer in a man in the Netherlands. Consideration of his previous treatment for leprosy and phenotyping of samples indicate the Buruli pathogen was acquired in Suriname and activated by trauma on return to the Netherlands. Awareness of this disease by clinicians in non-Buruli ulcer-endemic areas is critical for identification.
- 1 March 2015
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 21 (3) , 497-499
Open AccessBuruli Ulcer in Traveler from Suriname, South America, to the Netherlands
We report Buruli ulcer in a man in the Netherlands. Consideration of his previous treatment for leprosy and phenotyping of samples indicate the Buruli pathogen was acquired in Suriname and activated by trauma on return to the Netherlands. Awareness of this disease by clinicians in non-Buruli ulcer-endemic areas is critical for identification.
- Open Access
- 1 January 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (1) , 183-184
Cutaneous Leishmaniasis Acquired in Jura, France
- 1 January 2012
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 18 (1) , 183-184
Open AccessCutaneous Leishmaniasis Acquired in Jura, France
- 1 March 2010
- Published by Lepra in Leprosy Review
- Vol. 81 (1) , 82-86
Charles Louis Drognat Landré and Gerhard Henrik Armauer Hansen; Contribution from a Dutch Colony to the Discovery of the Leprosy Bacterium
- 1 March 2010
- Published by Lepra in Leprosy Review
- Vol. 81 (1) , 82-86
Charles Louis Drognat Landré and Gerhard Henrik Armauer Hansen; Contribution from a Dutch Colony to the Discovery of the Leprosy Bacterium
- 1 July 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 34 (5) , e196-e198
Cutaneous leishmaniasis with lymphadenopathy due toLeishmania donovani
Summary We describe a case of cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani, which was successfully treated with oral miltefosine. Given the increased prevalence of travelling, patients presenting with lymph-node enlargement should have leishmaniasis included in the differential diagnosis even in the absence of typical ulceratio
- 1 July 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 34 (5) , e196-e198
Cutaneous leishmaniasis with lymphadenopathy due toLeishmania donovani
Summary We describe a case of cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani, which was successfully treated with oral miltefosine. Given the increased prevalence of travelling, patients presenting with lymph-node enlargement should have leishmaniasis included in the differential diagnosis even in the absence of typical ulceratio
- 22 January 2009
- Published by Elsevier in Clinics in Dermatology
- Vol. 27 (2) , 237-239
Rudi Harold Cormane (1925-1987): a fabulous researcher and clinician
- 22 January 2009
- Published by Elsevier in Clinics in Dermatology
- Vol. 27 (2) , 237-239
Rudi Harold Cormane (1925-1987): a fabulous researcher and clinician
- 17 August 2006
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (7) , 739
Treatment of Recurrent Erythema Nodosum Leprosum with Infliximab
A 52-year-old woman with multibacillary (borderline lepromatous) leprosy, who had been treated intermittently with dapsone since 1965, presented to our department in 1996 with active skin lesions, a positive bacterial index (5+) on skin biopsy, and an elevated level of antibodies against Mycobacterium leprae specific to phenolic glycolipid I. She was treated with multidrug therapy (rifampin, dapsone, and clofazimine). One and a half years after treatment was started, disseminated painful erythematous nodules and plaques, or erythema nodosum leprosum, developed owing to an augmented immunologic response to mycobacterial antigens. These symptoms did not respond adequately to repeated courses of prednisolone (40 mg once daily), thalidomide (starting dose, 300 mg daily), and pentoxifylline (400 mg three times daily). It was not possible to discontinue the immunomodulating treatment because of the frequent reactivation of the erythema nodosum leprosum. Given the severity of the patient's symptoms despite the use of standard therapies, we considered alternative management strategies.
- 17 August 2006
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (7) , 739
Treatment of Recurrent Erythema Nodosum Leprosum with Infliximab
A 52-year-old woman with multibacillary (borderline lepromatous) leprosy, who had been treated intermittently with dapsone since 1965, presented to our department in 1996 with active skin lesions, a positive bacterial index (5+) on skin biopsy, and an elevated level of antibodies against Mycobacterium leprae specific to phenolic glycolipid I. She was treated with multidrug therapy (rifampin, dapsone, and clofazimine). One and a half years after treatment was started, disseminated painful erythematous nodules and plaques, or erythema nodosum leprosum, developed owing to an augmented immunologic response to mycobacterial antigens. These symptoms did not respond adequately to repeated courses of prednisolone (40 mg once daily), thalidomide (starting dose, 300 mg daily), and pentoxifylline (400 mg three times daily). It was not possible to discontinue the immunomodulating treatment because of the frequent reactivation of the erythema nodosum leprosum. Given the severity of the patient's symptoms despite the use of standard therapies, we considered alternative management strategies.
- 1 September 2004
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 151 (3) , 719-720
Atypical cutaneous mycobacteriosis diagnosed by polymerase chain reaction
- 1 September 2004
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 151 (3) , 719-720
Atypical cutaneous mycobacteriosis diagnosed by polymerase chain reaction
- 1 January 2003
- Published by Springer Nature
- Vol. 531, 295-297
Elimination of Leprosy and its Consequences for Research
- 1 January 2003
- Published by Springer Nature
- Vol. 531, 295-297
Elimination of Leprosy and its Consequences for Research